Bedrijfsoverzicht
NovaBay Pharmaceuticals, Inc. is an entity primarily engaged in the accumulation and holding of digital assets to participate in blockchain-based networks, with a specific focus on the decentralized Sky Protocol token known as SKY. The company operates within the Healthcare sector and the Biotechnology industry, though its operational activities are centered on digital asset deployment rather than traditional pharmaceutical development. NovaBay currently maintains a market capitalization of $51.92 million and employs two individuals to execute its strategic objectives. The combination of a market cap under $100 million and a lack of reported annual revenue figures suggests the company exists in an early-stage development phase where value creation is currently driven by asset accumulation rather than commercial product sales or revenue generation.
Financiële gezondheid
The company reported a net income of $-33,222,000 over the trailing twelve months, while its revenue and EBITDA figures are not available, indicating that the financial statements do not yet reflect significant commercial income streams. The absence of reported revenue alongside a substantial net loss reveals a cost structure dominated by operational expenses and asset-related costs that exceed any current income generation. Free cash flow stands at $-4,935,750, which indicates that the company is burning through cash reserves to fund its digital asset strategy and operational activities without generating sufficient cash inflows from sales. Margin analysis presents a complex picture: the gross margin is 0.0%, suggesting that cost of goods sold consumes all gross revenue or that no revenue is recognized in the traditional sense; conversely, the operating margin is reported at 350.1% and the profit margin at 0.0%, figures that typically arise in early-stage technology or asset-holding companies where accounting methods differ from standard manufacturing or service businesses. On the liability side, NovaBay holds $7.96 million in cash against a debt level of $776,000, resulting in a debt-to-equity ratio that is not applicable due to the nature of its equity structure or lack of traditional leverage. This substantial cash reserve relative to its minimal debt load indicates a conservative balance sheet stance regarding solvency, providing a buffer for ongoing operations. The current ratio is 7.60, a metric that signifies strong short-term liquidity, as the company possesses significantly more current assets than current liabilities to meet its obligations. Return on Equity is not applicable, while Return on Assets is -76.1%, a negative figure that reflects the erosion of asset value or the high cost of capital relative to the asset base at this specific point in the company's lifecycle.
Waarderingsbeoordeling
Valuation metrics for NovaBay present distinct characteristics typical of a pre-revenue biotechnology entity holding digital assets. The trailing twelve-month P/E ratio is not applicable given the lack of positive earnings, whereas the forward P/E is listed as -2.38, a negative figure that implies future earnings expectations remain negative or are not yet realized in the market's pricing model. The price-to-book ratio is -2.12, a negative multiple that indicates the market is pricing the company below its book value, a scenario often seen when assets are valued differently than their accounting book value or when liabilities exceed equity in the market's view. Alternative valuation metrics such as the price-to-sales ratio, which is not applicable due to missing revenue data, and the EV/EBITDA of -5.95, further underscore the company's status as an unprofitable entity where traditional revenue-based valuation models are not yet viable. Historical price data shows a 52-week high of $99.75 and a 52-week low of $1.11, highlighting extreme volatility within this specific trading range. Given the 52-week low of $1.11 and the high of $99.75, the stock price exhibits a wide dispersion, trading significantly below the recent highs while remaining above the absolute lows, reflecting the speculative nature of its asset holdings. The beta value is 0.16, which is substantially lower than the typical market beta of 1.0, indicating that the stock's price volatility is very low relative to the broader market movements, likely due to its niche positioning and low liquidity.
Growth & Income
Growth metrics for NovaBay are currently undefined, as the revenue growth year-over-year and earnings growth year-over-year figures are both not applicable. This lack of growth data implies that the company is not yet in a mature growth phase where historical performance can be extrapolated to predict future trajectories, and earnings are not growing faster than revenue because both are currently non-existent or negligible. As a non-dividend payer, NovaBay does not distribute a dividend yield or maintain a payout ratio, meaning the company retains all available capital to reinvest into its digital asset strategy and operational scaling rather than providing income to shareholders. Consequently, the overall growth and income profile is characterized by a total reliance on capital appreciation and asset value growth, offering no current yield and no historical growth rates to evaluate against peer benchmarks.